Internal Medicine
Online ISSN : 1349-7235
Print ISSN : 0918-2918
ISSN-L : 0918-2918
Preventive Effect of Sulfamethoxasole-trimethoprim on Pneumocystis jiroveci Pneumonia in Patients with Interstitial Pneumonia
Tatsuji EnomotoArata AzumaAki MatsumotoTakahito NeiKazue FujitaKumiko HattoriYoshinobu SaitoShinji AbeJiro UsukiShoji Kudoh
Author information

2008 Volume 47 Issue 1 Pages 15-20


Background Pneumocystis jiroveci pneumonia (PCP) is a potentially fatal complication in interstitial pneumonia patients receiving glucocorticoid therapy. Prophylaxis of PCP during glucocorticoid therapy is an important issue in the treatment of interstitial pneumonia.
Objective We evaluated the prophylactic effect of sulfamethoxasole-trimethoprim (TMP-SMX) in interstitial pneumonia patients receiving glucocorticoids.
Methods We retrospectively analyzed 74 interstitial pneumonia patients who received glucocorticoid therapy.
Results Seven of the 74 patients developed PCP. At the time of diagnosis of PCP, the mean duration of glucocorticoid therapy was 71 days and the mean daily dose of prednisolone was 37 mg. Among the 7 patients, the circulating CD4+ lymphocyte count was 370 /μl on average and it was over 200 /μl in 3 cases. The PCP patients showed a significant reduction of the lymphocyte count at 4 weeks after initiation of steroid therapy. None of the patients who received prophylactic TMP-SMX therapy developed PCP even if the CD4+ lymphocyte count was less than 200 /μl.
Conclusion Interstitial pneumonia patients receiving glucocorticoid therapy can benefit from TMP-SMX prophylaxis against PCP. Development of PCP cannot be ruled out in patients with a CD4+ lymphocyte count of greater than 200 /μl.

Content from these authors
© 2008 by The Japanese Society of Internal Medicine
Previous article Next article